Document is current

Any future updates will be listed below

Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer

Crossref DOI link: https://doi.org/10.1007/s00262-025-03999-0

Published Online: 2025-04-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark